Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78936
Title:
Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.
Authors:
Ewing, Joanne; Robertson, Jane D; Kell, W Jonathan; Burnett, Alan K; Ryder, W David J; Chang, James; Morgenstern, Godfrey R; Scarffe, J Howard; Chopra, Rajesh
Abstract:
The role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between observed and expected outcomes at 1 and 2 years, based on the predictive model derived from the MRC AML10 study. These data therefore indicate that only a third of eligible adult patients will undergo APBSCT. However, the results demonstrate favourable survival in such patients, with no transplant-related mortality.
Affiliation:
Department of Haematological Oncology, Christie Hospital, Manchester M20 4BX, UK. jewing@picr.man.ac.uk
Citation:
Autologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. 2003, 8 (2):83-90 Hematology
Journal:
Hematology
Issue Date:
Apr-2003
URI:
http://hdl.handle.net/10541/78936
DOI:
10.1080/1024533031000090793
PubMed ID:
12745657
Type:
Article
Language:
en
ISSN:
1024-5332
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorEwing, Joanne-
dc.contributor.authorRobertson, Jane D-
dc.contributor.authorKell, W Jonathan-
dc.contributor.authorBurnett, Alan K-
dc.contributor.authorRyder, W David J-
dc.contributor.authorChang, James-
dc.contributor.authorMorgenstern, Godfrey R-
dc.contributor.authorScarffe, J Howard-
dc.contributor.authorChopra, Rajesh-
dc.date.accessioned2009-08-27T14:44:16Z-
dc.date.available2009-08-27T14:44:16Z-
dc.date.issued2003-04-
dc.identifier.citationAutologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort. 2003, 8 (2):83-90 Hematologyen
dc.identifier.issn1024-5332-
dc.identifier.pmid12745657-
dc.identifier.doi10.1080/1024533031000090793-
dc.identifier.urihttp://hdl.handle.net/10541/78936-
dc.description.abstractThe role of autologous peripheral blood stem cell transplantation (APBSCT) in acute myeloid leukaemia (AML) remains controversial. The current study evaluated the application of APBSCT in a large consecutive series of patients with untreated AML, and compared outcome with a predictive model based on MRC AML10 data. Of 148 evaluable patients, 118 patients entered complete remission (CR) after induction therapy comprising three cycles of daunorubicin, cytosine arabinoside and oral 6-thioguanine. Of these patients, 68 (57%) proceeded to consolidation therapy with two courses of intermediate dose cytosine arabinoside, and stem cell mobilisation, and 40 of these patients (34%) underwent the APBSCT procedure after high dose busulphan conditioning. Harvest quality was the main factor precluding APBSCT. Five-year event-free survival (EFS) in patients who achieved CR was 38% and in APBSCT patients was 57%. There were no transplant-related deaths. No significant differences were demonstrated between observed and expected outcomes at 1 and 2 years, based on the predictive model derived from the MRC AML10 study. These data therefore indicate that only a third of eligible adult patients will undergo APBSCT. However, the results demonstrate favourable survival in such patients, with no transplant-related mortality.en
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subjectHaematopoietic Stem Cell Mobilisationen
dc.subject.meshAcute Disease-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBusulfan-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshCohort Studies-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCytarabine-
dc.subject.meshDaunorubicin-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshHematopoietic Stem Cell Mobilization-
dc.subject.meshHumans-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshLife Tables-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshModels, Biological-
dc.subject.meshPeripheral Blood Stem Cell Transplantation-
dc.subject.meshRemission Induction-
dc.subject.meshRisk-
dc.subject.meshSurvival Analysis-
dc.subject.meshThioguanine-
dc.subject.meshTransplantation Conditioning-
dc.subject.meshTransplantation, Autologous-
dc.subject.meshTreatment Outcome-
dc.titleAutologous peripheral blood stem cell transplantation in first remission adult acute myeloid leukaemia--an intention to treat analysis and comparison of outcome using a predictive model based on the MRC AML10 cohort.en
dc.typeArticleen
dc.contributor.departmentDepartment of Haematological Oncology, Christie Hospital, Manchester M20 4BX, UK. jewing@picr.man.ac.uken
dc.identifier.journalHematologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.